A-blockers for the management of lower urinary tract symptoms in patients with prostate cancer treated with external beam radiotherapy: a randomized controlled study.
A-blockers
External beam radiotherapy
Lower urinary tract symptoms
Prostate cancer
Radiotherapy
Urinary toxicity
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
14
05
2020
accepted:
01
08
2020
pubmed:
11
8
2020
medline:
18
9
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
This is a prospective study aiming to assess the efficacy of α-blockers in treating radiotherapy-induced symptoms of the lower urinary tract and its possible prophylactic role on acute urinary retention (AUR) in patients undergoing radical external beam radiotherapy (EBRT) for localized prostate cancer (PCa). Overall, 108 patients with localized PCa were recruited and randomly assigned in to two groups; 54 patients of Group 1 received tamsulosin 0.4 mg once daily with the initiation of EBRT and for 6 months and 54 patients of Group 2 served as the control group. All patients received radical EBRT and had post-void volume (Vres) assessment. The International Prostate Symptom Score (IPSS) questionnaire and evaluation of episodes of AUR were performed after the end of radiotherapy, at 3 and at 6 months. The incidence of AUR was significantly (p = 0.027) lower in group 1 compared to group 2. No independent predictive factors for AUR were identified in regression analysis. The IPSS changes in univariate and multivariate analysis at 3 months showed significant correlation with α-blockers only, while at 6 months showed significant correlation with Vres assessments (at 3 and 6 months) and with α-blockers. Side effects due to medication were mild and none of the patients discontinued the treatment. The selective use of α-blocker appears to prevent AUR in EBRT-treated patients. Although the administration of α-blockers might relieve patient-reported symptoms, there are no established independent predictive factors to distinguish patients who may benefit.
Sections du résumé
BACKGROUND
BACKGROUND
This is a prospective study aiming to assess the efficacy of α-blockers in treating radiotherapy-induced symptoms of the lower urinary tract and its possible prophylactic role on acute urinary retention (AUR) in patients undergoing radical external beam radiotherapy (EBRT) for localized prostate cancer (PCa).
METHODS
METHODS
Overall, 108 patients with localized PCa were recruited and randomly assigned in to two groups; 54 patients of Group 1 received tamsulosin 0.4 mg once daily with the initiation of EBRT and for 6 months and 54 patients of Group 2 served as the control group. All patients received radical EBRT and had post-void volume (Vres) assessment. The International Prostate Symptom Score (IPSS) questionnaire and evaluation of episodes of AUR were performed after the end of radiotherapy, at 3 and at 6 months.
RESULTS
RESULTS
The incidence of AUR was significantly (p = 0.027) lower in group 1 compared to group 2. No independent predictive factors for AUR were identified in regression analysis. The IPSS changes in univariate and multivariate analysis at 3 months showed significant correlation with α-blockers only, while at 6 months showed significant correlation with Vres assessments (at 3 and 6 months) and with α-blockers. Side effects due to medication were mild and none of the patients discontinued the treatment.
CONCLUSIONS
CONCLUSIONS
The selective use of α-blocker appears to prevent AUR in EBRT-treated patients. Although the administration of α-blockers might relieve patient-reported symptoms, there are no established independent predictive factors to distinguish patients who may benefit.
Identifiants
pubmed: 32776244
doi: 10.1007/s00345-020-03398-3
pii: 10.1007/s00345-020-03398-3
doi:
Substances chimiques
Adrenergic alpha-Antagonists
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1805-1813Références
Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. https://doi.org/10.3322/caac.21262
doi: 10.3322/caac.21262
pubmed: 25651787
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. https://doi.org/10.1002/ijc.29210
doi: 10.1002/ijc.29210
pubmed: 25220842
pmcid: 25220842
Kovács G, Pötter R, Loch T et al (2005) GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 74:137–148. https://doi.org/10.1016/j.radonc.2004.09.004
doi: 10.1016/j.radonc.2004.09.004
pubmed: 15734201
Hoskin PJ, Colombo A, Henry A et al (2013) GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 107:325–332. https://doi.org/10.1016/j.radonc.2013.05.002
doi: 10.1016/j.radonc.2013.05.002
pubmed: 23773409
Yamada Y, Rogers L, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11:20–32. https://doi.org/10.1016/j.brachy.2011.09.008
doi: 10.1016/j.brachy.2011.09.008
pubmed: 22265435
Davis BJ, Horwitz EM, Lee WR et al (2012) American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11:6–19. https://doi.org/10.1016/j.brachy.2011.07.005
doi: 10.1016/j.brachy.2011.07.005
pubmed: 22265434
Zelefsky MJ, Cowen D, Fuks Z et al (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85:2460–2468. https://doi.org/10.1002/(SICI)1097-0142(19990601)85:11<2460:AID-CNCR23>3.0.CO;2-N
doi: 10.1002/(SICI)1097-0142(19990601)85:11<2460::AID-CNCR23>3.0.CO;2-N
pubmed: 10357419
Zelefsky MJ, Pei X, Chou JF et al (2011) Dose Escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60:1133–1139. https://doi.org/10.1016/j.eururo.2011.08.029
doi: 10.1016/j.eururo.2011.08.029
pubmed: 21889832
Spratt DE, Pei X, Yamada J et al (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation thera. Internat J Radat Oncol Biol Phys 85:686–692. https://doi.org/10.1016/j.ijrobp.2012.05.023
doi: 10.1016/j.ijrobp.2012.05.023
Dearnaley DP, Jovic G, Syndikus I et al (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464–473. https://doi.org/10.1016/S1470-2045(14)70040-3
doi: 10.1016/S1470-2045(14)70040-3
pubmed: 24581940
Beckmann K, Garmo H, Nilsson P et al (2020) Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016. Acta Oncol 59:549–557. https://doi.org/10.1080/0284186X.2020.1730003
doi: 10.1080/0284186X.2020.1730003
pubmed: 32122185
Moris L, Cumberbatch MG, Van den Broeck T et al (2020) Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review. Eur Urol. https://doi.org/10.1016/j.eururo.2020.01.033
doi: 10.1016/j.eururo.2020.01.033
pubmed: 33172724
Rancati T, Palorini F, Cozzarini C et al (2017) Understanding urinary toxicity after radiotherapy for prostate cancer: first steps forward. Tumori J 103:395–404. https://doi.org/10.5301/tj.5000681
doi: 10.5301/tj.5000681
Carvalho ÍT, Baccaglini W, Claros OR et al (2018) Genitourinary and gastrointestinal toxicity among patients with localized prostate cancer treated with conventional versus moderately hypofractionated radiation therapy: systematic review and meta-analysis. Acta Oncol 57:1003–1010. https://doi.org/10.1080/0284186X.2018.1478126
doi: 10.1080/0284186X.2018.1478126
pubmed: 29882448
Matta R, Chapple CR, Fisch M et al (2019) Pelvic complications after prostate cancer radiation therapy and their management: an international collaborative narrative review. Eur Urol 75:464–476. https://doi.org/10.1016/j.eururo.2018.12.003
doi: 10.1016/j.eururo.2018.12.003
pubmed: 30573316
Marks LB, Carroll PR, Dugan TC, Anscher MS (1995) The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Internat J Radiat Oncol Biol Phys 31:1257–1280
doi: 10.1016/0360-3016(94)00431-J
Crawford ED, Kavanagh BD (2006) The role of α-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy. Am J Clin Oncol 29:517–523. https://doi.org/10.1097/01.coc.0000225412.24750.4c
doi: 10.1097/01.coc.0000225412.24750.4c
pubmed: 17023790
Mundy AR, Andrich DE (2012) Posterior urethral complications of the treatment of prostate cancer. BJU Internat 110:304–325. https://doi.org/10.1111/j.1464-410X.2011.10864.x
doi: 10.1111/j.1464-410X.2011.10864.x
Fransson P (2009) Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer – 15 years’ follow-up. A comparison with age-matched controls. Acta Oncol 47:852–861. https://doi.org/10.1080/02841860701654325
doi: 10.1080/02841860701654325
Kalogeridi M-A, Kyrgias G, Zygogianni A et al (2014) Challenges and choices in prostate cancer irradiation: from the three dimensional conformal radiotherapy to the era of intensity modulated, image-guided and adaptive radiation treatment. Urol J 11:1925–1931. https://doi.org/10.22037/uj.v11i06.2635
doi: 10.22037/uj.v11i06.2635
pubmed: 25433469
Anscher MS, Chen L, Rabbani Z et al (2005) Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Internat J Radiat Oncol Biol Phys 62:255–259
doi: 10.1016/j.ijrobp.2005.01.040
Dellis A, Deliveliotis C, Kalentzos V et al (2014) Is there a role for hyberbaric oxygen as primary treatment for grade IV radiation-induced haemorrhagic cystitis? A prospective pilot-feasibility study and review of literature. Internat Braz J Urol 40:296–305. https://doi.org/10.1590/S1677-5538.IBJU.2014.03.02
doi: 10.1590/S1677-5538.IBJU.2014.03.02
Andersson K-E, Hedlund P (2002) Pharmacologic perspective on the physiology of the lower urinary tract. Urology 60:13–20. https://doi.org/10.1016/S0090-4295(02)01786-7
doi: 10.1016/S0090-4295(02)01786-7
pubmed: 12493344
Zelefsky MJ, Ginor RX, Fuks Z, Leibel SA (1999) Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Internat J Radiat Oncol Biol Phys 45:567–570
doi: 10.1016/S0360-3016(99)00232-1
Skolarus TA, Wolf AMD, Erb NL et al (2014) American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 64:225–249. https://doi.org/10.3322/caac.21234
doi: 10.3322/caac.21234
pubmed: 24916760
Lepor H (2007) Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 9:181–190
pubmed: 18231614
pmcid: 2213889
Yuan J-Q, Mao C, Wong SY-S et al (2015) Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore) 94:e974. https://doi.org/10.1097/MD.0000000000000974
doi: 10.1097/MD.0000000000000974
Roehrborn CG (2006) Three months’ treatment with the α 1 -blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9:121–125. https://doi.org/10.1038/sj.pcan.4500849
doi: 10.1038/sj.pcan.4500849
pubmed: 16304557
Roehrborn CG, Siami P, Barkin J et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179:616–621. https://doi.org/10.1016/j.juro.2007.09.084
doi: 10.1016/j.juro.2007.09.084
pubmed: 18082216
Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. Eur Urol 57:123–131. https://doi.org/10.1016/j.eururo.2009.09.035
doi: 10.1016/j.eururo.2009.09.035
pubmed: 19825505
Djavan B, Fong YK, Harik M et al (2004) Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 64:1144–1148. https://doi.org/10.1016/j.urology.2004.08.049
doi: 10.1016/j.urology.2004.08.049
pubmed: 15596187
Karavitakis M, Kyriazis I, Omar MI et al (2019) Management of urinary retention in patients with benign prostatic obstruction: a systematic review and meta-analysis. Eur Urol 75:788–798. https://doi.org/10.1016/j.eururo.2019.01.046
doi: 10.1016/j.eururo.2019.01.046
pubmed: 30773327
Bosch JLHR, Hop WCJ, Kirkels WJ, Schröder FH (1995) The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. BJU Internat 75:622–630. https://doi.org/10.1111/j.1464-410X.1995.tb07421.x
doi: 10.1111/j.1464-410X.1995.tb07421.x
Boehmer D, Maingon P, Poortmans P et al (2006) Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 79:259–269. https://doi.org/10.1016/j.radonc.2006.05.012
doi: 10.1016/j.radonc.2006.05.012
pubmed: 16797094
Salembier C, Villeirs G, De Bari B et al (2018) ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol 127:49–61. https://doi.org/10.1016/j.radonc.2018.01.014
doi: 10.1016/j.radonc.2018.01.014
pubmed: 29496279
Bentzen SM, Constine LS, Deasy JO et al (2010) Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Internat J Radiat Oncol Biol Phys 76:S3–S9. https://doi.org/10.1016/j.ijrobp.2009.09.040
doi: 10.1016/j.ijrobp.2009.09.040
Kantzou I, Platoni K, Sandilos P et al (2011) Conventional versus virtual simulation for radiation treatment planning of prostate cancer: final results. J BUON 16:309–315
pubmed: 21766503
Kouloulias V, Antypas C, Liakouli Z et al (2015) The first implementation of IMRT technique for head and neck and prostate cancer patients in public sector in Greece: feasibility, treatment planning and dose delivery verification using the delta (4PT) Pre-Treatment volumetric quality assurance system. J BUON 20:196–205
pubmed: 25778316
Pinkawa M, Fischedick K, Asadpour B et al (2008) Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Internat J Radiat Oncol Biol Phys 70:83–89. https://doi.org/10.1016/j.ijrobp.2007.05.051
doi: 10.1016/j.ijrobp.2007.05.051
Aizer AA, Anderson NS, Oh SC et al (2011) The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy. Internat J Radiat Oncol Biol Phys 79:379–384. https://doi.org/10.1016/j.ijrobp.2009.11.023
doi: 10.1016/j.ijrobp.2009.11.023
Mazzola R, Fersino S, Fiorentino A et al (2016) The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy. Clin Transl Oncol 18:317–321. https://doi.org/10.1007/s12094-015-1371-2
doi: 10.1007/s12094-015-1371-2
pubmed: 26250766
Chen RC, Basak R, Meyer A-M et al (2017) Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 317:1141–1150. https://doi.org/10.1001/jama.2017.1652
doi: 10.1001/jama.2017.1652
pubmed: 28324092
pmcid: 6284802
Malik R, Jani AB, Liauw SL (2011) External beam radiotherapy for prostate cancer: urinary outcomes for men with high international prostate symptom scores (IPSS). Internat J Radiat Oncol Biol Phys 80:1080–1086. https://doi.org/10.1016/j.ijrobp.2010.03.040
doi: 10.1016/j.ijrobp.2010.03.040
Yan M, Xue P, Wang K et al (2017) Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? Strahlenther Onkol 193:714–721. https://doi.org/10.1007/s00066-017-1162-5
doi: 10.1007/s00066-017-1162-5
pubmed: 28612083
Tanaka N, Torimoto K, Asakawa I et al (2018) Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer—A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor—. Brachytherapy 17:537–543. https://doi.org/10.1016/j.brachy.2017.12.004
doi: 10.1016/j.brachy.2017.12.004
pubmed: 29402711
Oyama N, Aoki Y, Ito H et al (2014) Alpha 1-Adrenoceptor blocker may improve not only voiding but also storage lower urinary tract symptoms caused by 125I Brachytherapy for prostate cancer. ISRN Urol 14:654. https://doi.org/10.1155/2014/140654
doi: 10.1155/2014/140654
Tsumura H, Satoh T, Ishiyama H et al (2011) Comparison of Prophylactic Naftopidil, Tamsulosin, and silodosin for 125I Brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Internat J Radiat Oncol Biol Phys 81:e385–e392. https://doi.org/10.1016/j.ijrobp.2011.04.026
doi: 10.1016/j.ijrobp.2011.04.026
Merrick GS, Butler WM, Wallner KE et al (2002) Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 60:650–655. https://doi.org/10.1016/S0090-4295(02)01840-X
doi: 10.1016/S0090-4295(02)01840-X
pubmed: 12385927
Mabjeesh NJ, Chen J, Stenger A, Matzkin H (2007) Preimplant predictive factors of urinary retention after iodine 125 prostate Brachytherapy. Urology 70:548–553. https://doi.org/10.1016/j.urology.2007.04.042
doi: 10.1016/j.urology.2007.04.042
pubmed: 17905113
Allen ZA, Merrick GS, Butler WM et al (2005) Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Internat J Radiat Oncol Biol Phys 62:981–987. https://doi.org/10.1016/j.ijrobp.2004.12.068
doi: 10.1016/j.ijrobp.2004.12.068
Shimizu N, Minami T, Sugimoto K et al (2014) Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study. World J Urol 32:1423–1432. https://doi.org/10.1007/s00345-014-1239-z
doi: 10.1007/s00345-014-1239-z
pubmed: 24435207
Bentzen SM (2006) Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6:702–713. https://doi.org/10.1038/nrc1950
doi: 10.1038/nrc1950
pubmed: 16929324
Yu T, Zhang Q, Zheng T et al (2016) The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS ONE 11:e0154499. https://doi.org/10.1371/journal.pone.0154499
doi: 10.1371/journal.pone.0154499
pubmed: 27171271
pmcid: 4865138
Jackson WC, Silva J, Hartman HE et al (2019) Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Internat J Radiat Oncol Biol Phys 104:778–789. https://doi.org/10.1016/j.ijrobp.2019.03.051
doi: 10.1016/j.ijrobp.2019.03.051
Kishan AU, King CR (2017) Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer. Semin Radiat Oncol 27:268–278. https://doi.org/10.1016/j.semradonc.2017.02.006
doi: 10.1016/j.semradonc.2017.02.006
pubmed: 28577834